Doxycycline PEP for Sexually Transmitted Infection

Doxycyline given for post-exposure prophylaxis to men who have sex with men reduced the occurrence of chlamydia and syphilis but not gonorrhea.

Increasing rates of sexually transmitted infections (STIs) among men who have sex with men (MSM) have been noted, in particular among those on tenofovir/FTC pre-exposure prophylaxis (PrEP; NEJM JW Infect Dis Jan 2016 and N Engl J Med 2015 Dec 3; 373:2237). To assess if doxycycline given after unprotected sex (post-exposure prophylaxis [PEP]) decreased the incidence of STIs, investigators in France performed an open-label trial in which they randomized 232 participants taking tenofovir/FTC on-demand for PrEP 1:1 to either no prophylaxis or doxycycline (two 100-mg pills taken within 24 hours and no later than 72 hours after sex). The primary endpoint was the occurrence of a first STI (syphilis, chlamydia, or gonorrhea) after randomization.

At …

Reviewing Author

Carlos del Rio, MD

Disclosures

Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines

Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)

Carlos del Rio, MD

Disclosures

Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines

Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)

Doxycycline PEP for Sexually Transmitted Infection

Topics

Reviewing Author